other ssos those skilled in the art can appreciate that the invention as directed toward human tnf u03b1 receptors can be practiced using sso having a sequence that is complementary to at least 10 preferably between 15 and 20 nucleotides of the portions of the tnfr1 or tnfr2 genes comprising exons 7 or 8 and their adjacent introns it is further preferred that at least one nucleotide of the exon itself is included within the complementary sequence seq id nos 1 4 contain the sequence of exons 7 and 8 of the tnfr1 seq id nos 1 and 2 and tnfr2 seq id nos 3 and 4 and 50 adjacent nucleotides of the flanking introns when affinity enhancing modifications are used including but not limited to lna or g clamp nucleotides the skilled person recognizes the length of the sso can be correspondingly reduced when alternating conventional and lna nucleotides are used a length of 16 is effective the pattern of alternation of lna and conventional nucleotides is not important those skilled in the art will also recognize that the selection of sso sequences must be made with care to avoid self complementary sso which may lead to the formation of partial u201c hairpin u201d duplex structures in addition high gc content should be avoided to minimize the possibility of non specific base pairing furthermore ssos matching off target genes as revealed for example by blast should also be avoided in some situations it may be preferred to select an sso sequence that can target a human and at least one other species these ssos can be used.